JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
John G.T. Augoustides
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Augoustides, J. G.T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Augoustides, J. G.T.
Related Collections
Right arrow Anesthesia
Right arrow Cardiac - pharmacology
Right arrow Extracorporeal circulation

J Thorac Cardiovasc Surg 2008;136:1104
© 2008 The American Association for Thoracic Surgery

Letter to the Editor

Aprotinin and renal dysfunction: The role of exposure to angiotensin-converting enzyme inhibitors

John G.T. Augoustides, MD, FASE

Associate Professor, Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283

The first 20% of the full text of this article appears below.

To the Editor:

I read with great interest the recent article by Pagano and colleagues1Go detailing their favorable experience with aprotinin in a large patient series (N = 7836: 1998–2006) from a single institution. The authors demonstrated that aprotinin exposure did not significantly affect the incidence of postoperative renal dysfunction.

Careful review of . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.